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Abstract
Background: Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, has recently shown antitumor activity in
various cancer cells. Apo2 ligand or tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) is regarded as
a promising anticancer agent, but chemoresistance affects its efficacy as a treatment strategy. Apoptosis induced by the
combination of DHA and Apo2L/TRAIL has not been well documented, and the mechanisms involved remain unclear.
Methodology/Principal Findings: Here, we report that DHA enhances the efficacy of Apo2L/TRAIL for the treatment of
pancreatic cancer. We found that combined therapy using DHA and Apo2L/TRAIL significantly enhanced apoptosis in BxPC-
3 and PANC-1 cells compared with single-agent treatment in vitro. The effect of DHA was mediated through the generation
of reactive oxygen species, the induction of death receptor 5 (DR5) and the modulation of apoptosis-related proteins.
However, N-acetyl cysteine significantly reduced the enhanced apoptosis observed with the combination of DHA and
Apo2L/TRAIL. In addition, knockdown of DR5 by small interfering RNA also significantly reduced the amount of apoptosis
induced by DHA and Apo2L/TRAIL.
Conclusions/Significance: These results suggest that DHA enhances Apo2L/TRAIL-mediated apoptosis in human pancreatic
cancer cells through reactive oxygen species-mediated up-regulation of DR5.
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Introduction
Pancreatic cancer is one of the most lethal digestive system
malignancies and has a very poor prognosis [1,2]. Conventional
chemotherapy has shown limited survival benefit when combined
with surgical resection [3]. Thus, an effective treatment strategy
for pancreatic cancer is urgently needed.
Artemisinin (the active principle of the Chinese medicinal herb,
Artemisia annua [4,5]) and its derivatives are extremely effective
antimalarial drugs with few adverse side effects [6]. Dihydroarte-
misinin (DHA), a derivative of artemisinin, is a more water-soluble
and effective antimalarial than artemisinin [7]. Recently, it has
been demonstrated that DHA effectively kills various types of
cancer cells [8–13]. Furthermore, we have determined that DHA
can significantly inhibit cell growth and induce the apoptosis of
pancreatic cancer cells in a dose- and time-dependent manner but
is essentially non-toxic to normal cells [9]. In previous studies,
Agtmael [14] and O’Neill PM [5] demonstrated that artemisinin
contains an endoperoxide bridge, which is essential for the
reaction with iron to form reactive oxygen species (ROS).
Moreover, it has been demonstrated that cancer cells take up
increased amounts of iron to produce higher levels of intracellular
ROS than are found in normal cells [15]. Thus, it is likely that the
potency of DHA against cancer cells is related to the generation of
ROS [16], but the actual mechanism of DHA action is poorly
understood.
Apo2 ligand or tumor necrosis factor-related apoptosis-inducing
ligand (Apo2L/TRAIL) is a member of the TNF superfamily,
which serves as an effective anticancer agent due to its cancer cell
specificity and potent antitumor activity. Apo2L/TRAIL induces
apoptosis in cancer cells through interactions with death receptor 4
(DR4) and DR5, which form the death-inducing signal complex
(DISC) by binding to FADD and caspase-8 or caspase-10 [17–19].
The DISC then in turn initiates a protease cascade, which
activates downstream effector caspases, including caspase-3. In
addition, many apoptosis-related proteins downstream of the
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participate in Apo2L/TRAIL-induced apoptosis [20]. A number
of studies have shown that terpenoids can up-regulate the
expression of DR4 and/or DR5 in human cancer cells
[12,20,21]. Thus, agents that can up-regulate Apo2L/TRAIL
receptors and down-regulate anti-apoptotic proteins have the
potential to enhance the apoptotic effects of Apo2L/TRAIL. In
this study, we sought to determine the effect of DHA on Apo2L/
TRAIL-induced apoptosis in pancreatic cancer cells. Our results
show that DHA can potentiate the apoptotic effects of Apo2L/
TRAIL through up-regulation of DR5 expression in human
pancreatic cancer cells.
Results
DHA and Apo2L/TRAIL synergistically inhibit the growth
of pancreatic cancer cells
To determine whether DHA and Apo2L/TRAIL act synergis-
tically to inhibit the growth of pancreatic cancer cells, we
measured cell viability in BxPC-3 and PANC-1 cell lines in
response to different treatment regimens. Dose-dependent growth
inhibition was observed when BxPC-3 cells were treated with
either DHA (0–100 mmol/L) or Apo2L/TRAIL (0–200 ng/ml)
alone (Figure 1A left). However, treatment with higher doses of
DHA and Apo2L/TRAIL in combination (50 mmol/L and
100 ng/ml, respectively and 6 mmol/L and 200 ng/ml, respec-
tively) resulted in more potent growth inhibition than treatment
with either compound alone (Figure 1A left). To more accurately
determine the effects of combination therapy, data were examined
using median effect analysis to determine the type of interactions
which occurred, i.e. antagonism (CI.1), additivity (CI=1) or
synergism (CI,1). The synergistic effect (CI,1) was observed in
the combination therapy (Figure 1A right). Similarly, a suggestive
synergistic effect of DHA and Apo2L/TRAIL on cell growth was
observed in PANC-1 cells (data not shown).
Next, we performed a clonogenic assay to determine whether
DHA enhances the effect of Apo2L/TRAIL on long-term colony
formation. The cells were treated with DHA (50 mmol/L) and
Apo2L/TRAIL (100 ng/ml) either alone or in combination for
24 h. The cells were then washed with PBS, incubated in fresh
medium and, seven days later, were stained with crystal violet. The
clonogenic assay indicated that the number of surviving colonies in
the group that received the combination of DHA and Apo2L/
TRAIL was dramatically lower than in the groups treated with
DHA or Apo2L/TRAIL alone. These results indicate that the
combined treatment with DHA and Apo2L/TRAIL significantly
reduced the number of reproductive cells (Figure 1B and 1C).
DHA enhances Apo2L/TRAIL-induced apoptosis
dependent on reactive oxygen species
To determine whether the ability of DHA to enhance the
cytotoxicity of Apo2L/TRAIL was mediated by ROS-induced
apoptosis, we used flow cytometry and laser scanning confocal
microscopy to measure the rate of apoptosis and intracellular ROS
in BxPC-3 and PANC-1 cells.
BxPC-3 and PANC-1 cells were treated with DHA (50 mmol/L)
and/or Apo2L/TRAIL (100 ng/ml). Following 72 h of treatment,
the cells were stained with Annexin V and propidium iodide (PI),
subjected to flow cytometry and viewed by laser scanning confocal
microscopy to measure the rate of apoptosis. Representative
histograms from the flow cytometry experiments indicate that the
rates of apoptosis of control BxPC-3 cells and cells treated with
DHA, Apo2L/TRAIL or the combination of both were 5.1%,
29.4%, 15.5% and 47.8%, respectively (Figure 2A). With respect
to the PANC-1 cells, the rates of apoptosis were 6.7%, 18.6%,
11.9% and 45.8%, respectively. Thus, treatment with DHA or
Apo2L/TRAIL alone significantly increased the rate of apoptosis
of BxPC-3 cells compared with the controls (both P,0.05).
Furthermore, treatment with the combination of DHA and
Apo2L/TRAIL led to a further increase in the rate of apoptosis
compared with treatment with DHA or Apo2L/TRAIL alone
(both P,0.01). Similar results were obtained with PANC-1 cells.
The extent of apoptosis, as detected by Annexin V labeling,
approximates the reduction in cell viability following treatment
with DHA, Apo2L/TRAIL or the combination of both, suggesting
that apoptosis accounts for most of the observed cytotoxicity.
However, pretreatment with N-acetyl cysteine (NAC, 10 mM) was
able to significantly reduce the amount of apoptosis caused by the
combined treatment of DHA and Apo2L/TRAIL in BxPC-3 and
PANC-1 cells (both P,0.01). Taken together, these data indicate
that ROS mediates the ability of DHA to enhance Apo2L/
TRAIL-induced apoptosis. The use of laser scanning confocal
microscopy confirmed the increased apoptosis measured by flow
cytometry, as shown in the representative photographs (Figure 2B).
BxPC-3 and PANC-1 cells treated with DHA and Apo2L/TRAIL
displayed more numerous early- and late-stage apoptotic cells than
the controls, which had very few early-stage apoptotic cells.
BxPC-3 and PANC-1 cells were incubated with DHA
(50 mmol/L), Apo2L/TRAIL (100 ng/ml) or the combination of
both for 12 h, and DCF fluorescence was recorded as a measure of
intracellular ROS levels. As shown in Figure 2C, the levels of
intracellular ROS were significantly (P,0.01) higher in cells that
had been treated with DHA and the combination of DHA and
Apo2L/TRAIL than in control cells. However, Apo2L/TRAIL
treatment alone had little effect on intracellular ROS levels in
BxPC-3 and PANC-1 cells. To confirm that ROS generation is
responsible for enhancing Apo2L/TRAIL-induced apoptosis, the
cells were pretreated with 10 mM NAC, a well-known inhibitor of
ROS production, for 6 h and then incubated with the combina-
tion of DHA and Apo2L/TRAIL. Laser scanning results indicate
that pretreatment with NAC significantly (P,0.05) reduced the
level of intracellular ROS in all cell types compared with the cells
treated with DHA and Apo2L/TRAIL alone. Confocal micros-
copy in combination with DCFHDA staining, where green
fluorescence represents the intracellular ROS (Figure 2D), re-
vealed that intracellular ROS was significantly (P,0.01) higher in
DHA-treated cells than in control cells. However, pretreatment
with NAC significantly (P,0.05) reduced the mean fluorescence
intensity in the DHA- and Apo2L/TRAIL-treated cells
(Figure 2E).
DHA regulates apoptosis-related gene expression
Next, we analyzed the expression of apoptosis-related genes
mediated by ROS after treatment with DHA. BxPC-3 and PANC-
1 cells were treated with various concentrations of DHA (0, 25, 50
and 100 mmol/L) or pretreated with NAC (10 mM) followed by
the addition of DHA (100 mmol/L) for 72 h, and the expression
levels of Bcl-2, Bax, surviving, caspase-3, caspase-8 and caspase-9
were detected by western blot analysis. In response to DHA, the
expression levels of Bax, caspase-3, caspase-8 and caspase-9 were
significantly up-regulated, whereas Bcl-2 expression decreased in
a dose-dependent manner, and the expression of survivin
remained unchanged in the BxPC-3 and PANC-1 cells. In-
terestingly, pretreatment with NAC (10 mM) blocked the ability of
DHA to up-regulate the expression of caspase-8, Bax, caspase-9
and caspase-3. It was also found that DHA significantly enhanced
Apo2L/TRAIL-mediated apoptosis in both cell lines, and this
DHA Enhances TRAIL-Mediated Apoptosis
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and caspase-3 (Figure 3).
DHA-induced up-regulation of DR5 is dependent on
reactive oxygen species
We next examined whether ROS was involved in DHA-
induced DR5 expression. BxPC-3 and PANC-1 cells were treated
with various concentrations of DHA for 48 h, whole cell extracts
were prepared and the expression of DR5 protein was examined.
Figure 1. DHA synergistically enhances Apo2L/TRAIL-induced cell death in BxPC-3 cells. (A) Cells were treated with DHA alone, Apo2L/
TRAIL alone or a combination of the two agents and incubated at 37uC for 72 h. The viability of the cells was assessed using the MTT method.
Combination index (CI) versus fraction affected (Fa) plots obtained from median-effect analysis of Chou-Talalay. A CI.1 indicates antagonism, =1
indicates additivity, and ,1 indicates synergy. (B) The clonogenic assay was performed as described in the Materials and Methods section. The cells
were treated with DHA (50 mmol/L) alone, Apo2L/TRAIL (100 ng/ml) alone or the combination of the two drugs for 24 h and washed with PBS. The
cells were then incubated for an additional 7 d and stained with crystal violet. (C) Clonogenic survival is presented as the percentage of surviving
colonies formed in drug-treated cells with respect to untreated cells.
doi:10.1371/journal.pone.0037222.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37222Figure 2. DHA-induced apoptosis is caused by ROS. (A) Apoptosis of pancreatic cancer cells. BxPC-3 and PANC-1 cells were treated with DHA
(50 mmol/L) and Apo2L/TRAIL (100 ng/ml) as indicated. Flow cytometry was performed to measure apoptosis rates (%). A significant increase in the
apoptosis rate compared with the control is denoted by ‘‘*’’ (P,0.05), a significant increase compared with DHA- or Apo2L/TRAIL-treated cells is
denoted by ‘‘{’’ (P,0.01), and a significant decrease compared with DHA+Apo2L/TRAIL-treated cells is denoted by ‘‘{’’ (P,0.01). Representative
DHA Enhances TRAIL-Mediated Apoptosis
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37222We found that DHA had dose-dependent effects on the expression
of DR5 (Figure 4A). Thus, we sought to determine whether the
generation of ROS is directly associated with the ability of DHA to
induce DR5 expression. FACS detection showed that treatment of
BxPC-3 and PANC-1 with DHA increased intracellular ROS
levels in a dose-dependent manner, and the DHA-induced
increase in ROS levels was significantly blocked by pretreatment
with 10 mM NAC (Figure 4B). Importantly, pretreatment with
NAC markedly inhibited the DHA-induced up-regulation of DR5
expression (Figure 4A).
We next examined whether scavenging of ROS could attenuate
the Apo2L/TRAIL-induced cell death enhanced by DHA. As
histograms from cytometrically analyzed BxPC-3 and PANC-1 cells treated with control, DHA, Apo2L/TRAIL, DHA+Apo2L/TRAIL or NAC (10 mM). (B)
Laser scanning confocal microscopy of cells. Representative photographs were taken of the control BxPC-3 and PANC-1 cells and of BxPC-3 and
PANC-1 cells treated with DHA+Apo2L/TRAIL and DHA+Apo2L/TRAIL+NAC. (C) Levels of intracellular ROS measured in vitro. BxPC-3 and PANC-1 cells
were treated with DHA (50 mmol/L), Apo2L/TRAIL (100 ng/ml), DHA+Apo2L/TRAIL, or pretreated with NAC (10 mM) and then treated with
DHA+Apo2L/TRAIL for 6 h. Untreated cells served as the control. The cells were incubated with DCFHDA and then subjected to flow cytometry to
measure the levels of intracellular ROS, as represented by DCF fluorescence. A significant increase in DCF fluorescence compared with the control is
denoted by ‘‘*’’ (P,0.05), a highly significant difference compared with the control is denoted by ‘‘**’’ (P,0.01), and a significant reduction compared
with the DHA+Apo2L/TRAIL treatment is denoted by ‘‘{’’ (P,0.05). (D) Representative photographs are shown for DCFHDA-stained cells observed
using laser scanning confocal microscopy. The green fluorescence represents intracellular ROS. (E) The mean fluorescence intensity was measured for
the DCFHDA-stained cells, and the respective 3-dimensional horizontal plane images were produced by laser scanning confocal microscopy. A
significant difference from the control is denoted by ‘‘*’’ (P,0.01), and a significant difference from the DHA+Apo2L/TRAIL treatment is denoted by
‘‘{’’ (P,0.05).
doi:10.1371/journal.pone.0037222.g002
Figure 3. The expression of apoptosis-related genes. BxPC-3 and PANC-1 cells were treated with various concentrations of DHA (0, 25, 50,
100 mmol/L) and pretreated with NAC followed by DHA (100 mmol/L) for 72 h. Whole cell extracts were prepared and analyzed by western blotting
using antibodies against Bcl-2, Bax, surviving, caspase-3, caspase-8, and caspase-9. DHA significantly up-regulated the expression of Bax, caspase-3,
caspase-8 and caspase-9, and down-regulated the expression of Bcl-2. However, DHA had little influence on the expression of survivin. DHA with NAC
(10 mM) pretreatment did not up-regulate the expression of caspase-8, Bax, caspase-9, and caspase-3. b-actin served as an internal control.
doi:10.1371/journal.pone.0037222.g003
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induced cell death in BxPC-3 and PANC-1 cells. However,
pretreatment with NAC significantly reduced the ability of DHA
to induce cell death from 63% to 14% in BxPC-3 cells and from
31% to 17% in PANC-1 cells. Taken together, these data indicate
that the ROS-mediated up-regulation of DR5 is critical for the
observed DHA enhancement of Apo2L/TRAIL-induced apopto-
sis.
Figure 4. Up-regulation of DR5 by DHA was mediated by ROS. (A) BxPC-3 and PANC-1 cells were treated with the indicated doses of DHA for
48 h. Whole cell extracts were prepared and analyzed for DR5 expression using western blotting. DHA had dose-dependent effects on the expression
of DR5. The DHA-induced increase in DR5 levels was significantly blocked by pretreatment with 10 mM NAC. b-actin served as an internal control. (B)
The cells were collected and analyzed using flow cytometry. A gradual increase in fluorescence was observed in cells treated with 25, 50 and
100 mmol/L DHA, respectively, indicating a dose-dependent increase in the production of ROS in response to DHA treatment in the two cell lines. The
production of ROS was markedly inhibited by pretreating the cells with NAC (10 mM). (C) The cells were treated with DHA (50 mmol/L) alone, Apo2L/
TRAIL (100 ng/ml) alone or a combination of the two agents. The cells were also treated with NAC (10 mM) alone or pretreated with NAC and
incubated at 37uC for 72 h. The viability of the cells was assessed using the MTT method and the viability index (%) was calculated. Significant
differences are denoted by ‘‘*’’ (P,0.01).
doi:10.1371/journal.pone.0037222.g004
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regulated DR5 expression
We also investigated whether DHA-mediated DR5 expression is
required for Apo2L/TRAIL-induced apoptosis in pancreatic
cancer cells. To determine the role of DR5 in Apo2L/TRAIL-
induced apoptosis, we used siRNAs to down-regulate DR5
expression. We next examined whether the suppression of DR5
by siRNA could abrogate the sensitizing effects of DHA on
Apo2L/TRAIL-induced cell death. Transfection of cells with
DR5 siRNA increased the viability of BxPC-3 cells by 47%
(P,0.01) and the viability of PANC-1 cells by 42% (data not
shown), compared with the combination treatment alone
(Figure 5); treatment with control siRNA had no effect (Figure 5).
These results reveal, therefore, that the effect of DHA on Apo2L/
TRAIL-induced apoptosis had been effectively abolished in the
cells that were transfected with DR5 siRNA, indicating that DR5
is a major mediator of Apo2L/TRAIL-induced apoptosis.
DHA and Apo2L/TRAIL significantly inhibit the growth of
human pancreatic cancer cells in vivo
To investigate the effect of DHA and/or Apo2L/TRAIL on cell
growth in vivo, BxPC-3 cells were subcutaneously xenografted in
nude mice. Neither the DHA nor the Apo2L/TRAIL groups
demonstrated a significant reduction in tumor volume compared
with the control group (P,0.05). However, mice treated with the
combination of DHA and Apo2L/TRAIL had tumors that were
not only significantly smaller than the control (P,0.01), but were
also smaller than those treated with either agent alone (P,0.05),
demonstrating higher suppression on tumor growth in vivo
(Figure 6A and B). Western blot analysis of tumor tissue lysates
also revealed that the expression levels of DR5, caspase-3 and
caspase-8 were significantly up-regulated in the group treated with
the combination therapy and to a higher extent than the groups
treated with either DHA or Apo2L/TRAIL alone (Figure 6C).
These results are consistent with our in vitro studies, providing
further evidence that DHA can potentiate the antitumor activity of
Apo2L/TRAIL in vivo.
Cell proliferation marker PCNA and cell apoptosis were further
examined in situ in tumor samples from the four groups. As shown
in Figure 6D and E, DHA or Apo2L/TRAIL treated groups had
reduced expression of PCNA compared to control group
(P,0.05). While mice treated with the combination of DHA and
Apo2L/TRAIL had expression of PCNA that was not only lower
than the control (P,0.01), but was also lower than either agent
treated alone (P,0.05). Mono-therapy with either DHA or
Apo2L/TRAIL produced significantly higher apoptosis than
control (P,0.05), while combined therapy produced even more
apoptosis not only than the control (P,0.01), but also than groups
treated with single agent (P,0.05, Figure 6D and F).
Discussion
In the present study, we show that DHA, a semisynthetic
derivative of artemisinin, can enhance the apoptotic effect of
Apo2L/TRAIL against pancreatic cancer cells. DHA acts
synergistically with Apo2L/TRAIL to inhibit proliferation and
induce apoptosis through the ROS-mediated up-regulation of
DR5 in both BxPC-3 and PANC-1 cells. Furthermore, we
demonstrated that DHA can sensitize pancreatic cancer cells to
Apo2L/TRAIL treatment in vivo.
Soluble Apo2L/TRAIL, which is emerging as an attractive
anticancer agent, has been evaluated in several clinical trials.
However, many reports indicate that the majority of pancreatic
carcinoma cell lines are resistant to Apo2L/TRAIL [22–25].
Cancer cell resistance to Apo2L/TRAIL is one of the greatest
barriers to the further exploitation of this therapy. Thus, agents
that can either potentiate the effect of Apo2L/TRAIL or
overcome resistance are urgently needed [26]. The goals of this
study were to determine whether combining DHA with Apo2L/
TRAIL could promote synergistic antitumor activity and to
understand the exact mechanism by which combination therapy
using these agents elicits pancreatic cancer cell death in vitro and in
vivo.
Although many neoplasms display some resistance to Apo2L/
TRAIL in clinical trials, a growing body of data demonstrates that
Apo2L/TRAIL can selectively kill cancer cells without harming
normal cells, which could alleviate many side effects of conven-
tional chemotherapy. Notably, many reports have shown that
some plant extracts and chemotherapeutic agents can sensitize
cancer cells to Apo2L/TRAIL-induced cell death [17,26–29],
indicating that Apo2L/TRAIL resistance can be overcome with
the use of effective sensitizers. Recently, DHA has been shown to
produce strong antitumor effects either alone or in combination
Figure 5. Effects of knockdown of DR5 expression on DHA-induced cytotoxicity and cell apoptosis of Apo2L/TRAIL. BxPC-3 and
PANC-1 cells were transfected with DR5 siRNA and control siRNA, either alone or in combination. After 48 h, the cells were treated with 50 mmol/L
DHA for 24 h, and whole cell extracts were subjected to western blotting to test for the expression of DR5. Transfection of cells with siRNA targeting
DR5 specifically silenced the expression of DR5. The cells were seeded on a chamber slide and transfected with siRNAs. After 48 h, the cells were
treated with 50 mmol/L DHA, 100 ng/mL Apo2L/TRAIL, either alone or in combination, and incubated at 37uC for 72 h. The viability of the cells was
assessed using the MTT method, and the viability index (%) was calculated. Silencing of DR5 by siRNA reduced the cytotoxic effect of the combination
of DHA and Apo2L/TRAIL but not of DHA alone. Significant differences are denoted by ‘‘*’’ (P,0.01).
doi:10.1371/journal.pone.0037222.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37222Figure 6. Tumor growth, tumor gene expression, tumor proliferation and apoptosis in vivo. (A) BxPC-3 tumors were established
subcutaneously in mice. When the tumors reached approximately 120 mm
3 in volume, the mice were randomly assigned to control, DHA, Apo2L/
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various kinds of carcinoma in vitro and in vivo [8–10,30–32].
Meanwhile, the effect of DHA against pancreatic cancer has been
confirmed in our previous studies [9,30]. However, it is unknown
whether DHA and Apo2L/TRAIL act synergistically against
pancreatic cancer. In the present study, we found that the
combination of DHA and Apo2L/TRAIL resulted in significantly
greater growth inhibition of BxPC-3 and PANC-1 cells in vitro than
when either agent was used alone. Our results indicate that DHA
can synergistically enhance Apo2L/TRAIL-mediated cytotoxicity
and sensitize human pancreatic cancer cell lines to Apo2L/
TRAIL-induced apoptosis.
Several reports have shown that ROS generation is involved in
Apo2L/TRAIL-mediated apoptosis [33,34]. ROS is also generally
accepted to be associated with tumorigenesis and metastasis,
although this correlation is often complex and contradictory [35].
In fact, most anti-neoplastic agents have well-established mechan-
isms of action that involve the generation of ROS [36]. In cancer
cells, drug-induced oxidative stress superimposes on intrinsic
oxidative stress, resulting in a potent ROS-mediated cytotoxic
response that preferentially kills tumor cells or inhibits their
proliferation [37]. An endoperoxide bridge in artemisinin reacts
with intracellular iron to generate free radicals, which can lead to
macromolecular damage and cell death [38,39]. DHA, a derivative
of artemisinin, has been shown to cause the death of human
papillomavirus-expressing cell lines by inducing oxidative stress
that leads to the generation of ROS [8]. Recent work has also
demonstrated that cultured human metastatic melanoma cells are
sensitive to DHA-induced apoptosis and exhibit up-regulation of
cellular oxidative stress, phosphatidylserine externalization and
procaspase-3 cleavage [40]. In our study, we found that the levels
of intracellular ROS significantly increased by DHA treatment in
the presence and absence of Apo2L/TRAIL, whereas treatment
with Apo2L/TRAIL alone had little effect on intracellular ROS in
BxPC-3 and PANC-1 cells. We also found that the ability of DHA
to enhance Apo2L/TRAIL-induced apoptosis could be attenuated
by pretreatment with NAC. Therefore, our results provide a novel
mechanism by which DHA can act synergistically with Apo2L/
TRAIL to exert their combined pro-apoptotic effects in pancreatic
cancer, at least in part through ROS generation. In colon cancer
cells, apoptosis induced by Apo2L/TRAIL alone is also regulated
by the generation of ROS [41].
Two primary pathways are known to initiate cellular apoptosis:
the death receptor-induced, extrinsic pathway and the intrinsic,
mitochondrial pathway [42,43]. We previously reported that DHA
could trigger the mitochondrial pathway to induce apoptosis by
regulating the expression of Bcl-2 and Bax, leading to the release
of cytochrome c from the mitochondria and activating the
downstream initiator caspase-9, resulting in the activation of the
effector caspases and the induction of apoptosis [44]. However,
several studies have illustrated that Apo2L/TRAIL resistance in
cancer cell lines involves the expression of the anti-apoptotic
protein c-FLIP and down-regulation of the pro-apoptotic protein
caspase-8 [20,27,45]. Some chemotherapeutic agents, including
zerumbone [20] and garcinol [27], can significantly down-regulate
the expression of c-FLIP and/or up-regulate the expression of
caspase-8 through ROS to increase the sensitivity of cells to
Apo2L/TRAIL. It is recognized that caspase-8 is a direct
downstream target of DR5, and pro-caspase-8 recruits DISC to
activate caspase-8, resulting in activation of downstream effector
caspases [46]. In our study, DHA up-regulates caspase-8
expression in a dose-dependent manner to initiate cellular
apoptosis. We also show that DHA modulates the expression of
DR5 in a dose-dependent manner and that the increased
expression of DR5 is linked to the observed changes in oxidative
stress. Our data indicate that ROS is one of the upstream
regulators responsible for the DHA-mediated induction of DR5
and that DHA can potentiate Apo2L/TRAIL-induced cell
apoptosis through the extrinsic death-receptor pathways. These
results are consistent with those reported in a previous study [20].
The crosstalk between these two pathways is likely due to caspase-
8-mediated cleavage of Bid and its subsequent translocation to the
mitochondria where it initiates the intrinsic apoptosis pathway
[28]. Taken together, these results suggest that, in addition to the
mitochondrial-mediated apoptotic pathways, DHA-dependent
ROS generation also plays a pivotal role in the synergistic
enhancement of Apo2L/TRAIL-induced apoptosis via the
extrinsic death-receptor pathways in pancreatic cancer cells.
Here, we successfully used the ROS scavenger, NAC, to inhibit
oxidative stress. We also found that NAC abolished the ability of
DHA to induce DR5 expression, which is consistent with previous
reports regarding cancer chemopreventive agents, including DHA
[12], curcumin [47], sulforaphane [48] and zerumbone [20]. To
further investigate whether down-regulation of DR5 could
attenuate Apo2L/TRAIL chemosensitivity, we utilized siRNAs
to deplete cells of DR5. We found that DR5 siRNA significantly
reduced the expression of DR5 in BxPC-3 and PANC-1 cells. The
depletion of DR5 by siRNA significantly attenuated apoptosis in
response to the combination therapy, indicating that the ability of
DHA to augment Apo2L/TRAIL-induced apoptosis is mediated
by up-regulation of DR5. These results are similar to those found
in previous reports which demonstrate that down-regulation of
DR5 expression efficiently reduces the sensitization to Apo2L/
TRAIL-induced apoptosis by tunicamycin [49]. Taken together,
these findings show that DHA can enhance Apo2L/TRAIL-
mediated apoptosis through ROS-mediated up-regulation of DR5.
Using xenograft models, we found that the volume of tumors in
mice treated with the combination of DHA and Apo2L/TRAIL
remained essentially unchanged over the course of our study,
whereas tumor volume increased considerably in the control group
and, to a lesser extent, in the groups treated with either DHA or
Apo2L/TRAIL alone. These results are consistent with those of
our in vitro studies, demonstrating that DHA potentiates the
antitumor activity of Apo2L/TRAIL.
In summary, we conclude that DHA can potentiate Apo2L/
TRAIL-mediated apoptosis in pancreatic cancer cells through
ROS-mediated up-regulation of DR5. Considering that DHA is
not toxic to normal cells and that Apo2L/TRAIL is selective to
tumor cells, we predict that the use of a combination of DHA with
Apo2L/TRAIL could be a safe and effective treatment compared
TRAIL, or DHA+Apo2L/TRAIL groups and treated as described in the methods section. The sizes (measured in mm
3) of the tumors were monitored
and recorded. A significant difference in tumor volume from the control is denoted by ‘‘*’’ (P,0.05), and a significant reduction compared to the DHA
or Apo2L/TRAIL-treated tumors is denoted by ‘‘**’’ (P,0.01). (B) Representative animals and tumors are shown for each group. (C) Tumors from
control mice and from mice treated with DHA, Apo2L/TRAIL, and DHA+Apo2L/TRAIL were homogenized and subjected to western blot analysis to
detect the expression of caspase-3 and caspase-8. b-actin served as an internal control. (D) Analysis of proliferation marker PCNA by
immunohistochemistry and apoptotic status of tumor cells by in situ TUNEL assay. PCNA positive (E) and TUNEL-positive (F) cells were also counted
under microscope to calculate the proliferation index and apoptotic index, respectively. ‘‘*’’: P,0.05, compared with control. ‘‘**’’: P,0.01, compared
with single agent.
doi:10.1371/journal.pone.0037222.g006
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tions for the use of Apo2L/TRAIL as a cancer therapy, especially
for tumors that develop resistance to Apo2L/TRAIL. Importantly,
xenograft studies confirmed that DHA potentiates the antitumor
activity of Apo2L/TRAIL in vivo. Thus, these results indicate that
treatment with the combination of DHA and Apo2L/TRAIL may
support a novel therapeutic strategy against pancreatic cancer in
clinical settings.
Materials and Methods
Reagents, cell lines and cell culture
Human pancreatic cancer cell lines BxPC-3 and PANC-1 were
obtained from the Institute of Biochemistry and Cell Biology at the
Chinese Academy of Sciences, Shanghai, China. The cells were
routinely cultured at 37uC in RPMI 1640 medium supplemented
with 10% fetal calf serum, penicillin (100 U/ml) and streptomycin
(100 mg/ml) in a CO2 incubator. All cell lines were routinely
screened for mycoplasma contamination, using the Mycoplasma
Stain Assay Kit (Beyotime Institute of Biotechnology, Beijing,
China). The antibodies (ABs) against caspase-9, Bcl-2, caspase-3,
Bax, surviving, PCNA and b-actin were purchased from Santa
Cruz Biotechnology, California, USA. The anti-caspase-8 AB was
purchased from Cell Signaling Inc., Massachusetts, USA. The
anti-DR5 AB was obtained from Biosynthesis Biotechnology Co.
Ltd., Beijing, China. Annexin V-FITC and propidium iodide (PI)
were purchased from BaoSai Biotechnology Co. Ltd., Beijing,
China. Soluble recombinant human Apo2L/TRAIL was pur-
chased from PeproTech, USA. DHA was obtained from Sigma-
Aldrich, St. Louis, Missouri, USA. Working solutions were
prepared by dissolving the compound in dimethyl sulfoxide
(DMSO). The final concentration of DMSO was less than 1%
in all experiments.
Cell viability assay
Cell viability was measured using MTT and crystal violet assays.
BxPC-3 (4610
3) and PANC-1 (3610
3) cells were seeded onto 96-
well plates. After overnight culture, the cells were treated with
various concentrations of DHA, Apo2L/TRAIL or a combination
of the two compounds for 72 h. Control cells were cultured in
RPMI 1640 medium. After treatment, the medium was changed
from a complete culture medium to a serum- and pH indicator-
free medium, then the cell lines were incubated with MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) at 37uC
for 4 h. The medium was discarded, and DMSO was added to
each well at room temperature for 20 min, the absorbance was
measured at 490 nm on a plate reader and the optical density
(OD) was recorded. The highest concentration of Apo2L/TRAIL
and DHA as single agents and in combination do not interfere
with the MTT assay reagents, in the absence of cells (data not
shown). The growth index (%) was calculated according to the
formula: experimental OD value/control OD value 6100. All
experiments were repeated in triplicate.
Clonogenic assay
BxPC-3 and PANC-1 (3610
4/well) cells were seeded onto 6-
well plates and cultured overnight. The medium was then replaced
with complete culture medium containing various concentrations
of DHA, Apo2L/TRAIL or a combination of the two compounds
for an additional 24 h. Following drug exposure, the medium was
replaced with fresh medium, and all cultures were incubated for an
additional 7 days. The cells were then washed twice with pre-
warmed PBS, and the remaining cells were stained for 2 h with
a crystal violet solution (0.5% crystal violet, 20% methanol). After
removal of the crystal violet solution, the plates were washed three
times by immersion in a beaker filled with tap water. The plates
were left to dry at 37uC, and the images were analyzed as
described previously [50].
Calculation of the combination index (CI)
After concentration-effect curves were generated for each agent,
data were analyzed using the median-effect principle, which uses
the method of Chou and Talalay [51], to determine whether
combination treatment yields greater effects than expected from
summation alone. A CI.1 indicates antagonism, =1 indicates
additivity, and ,1 indicates synergy [52].
Annexin V and propidium iodide staining
The cells were treated as described above for 48 h, harvested,
washed with PBS and the numbers of cells were counted. The cells
(1610
5) were suspended in 100 ml of binding buffer and incubated
with 5 ml of Annexin V and 5 ml of PI for 15 min at room
temperature in the dark. The cell apoptosis rate (%) was measured
using a Beckman Coulter Epics Altra II cytometer (Beckman
Coulter, California, USA). A laser scanning confocal microscope
(LSM-510, Carl Zeiss Jena GmbH, Jena, Germany) was used to
visualize cells that had undergone apoptosis.
Measurement of ROS generation
This assay is based on the incorporation of 29,79-dichlorofluor-
escein (DCF) diacetate into the cell. H2O2 and peroxidases are
able to oxidize cleaved DCFH to DCF, which is highly fluorescent
at 530 nm. The cells were plated at a density of 1610
5 in 6-well
plates, allowed to attach overnight, and exposed to different
concentrations of DHA for 4 h. The cells were then incubated
with 10 M DCFHDA for 20 min at 37uC in a 5% CO2 incubator,
washed and resuspended in PBS at 1610
6 cells/ml. The cells were
analyzed by flow cytometry at an excitation wavelength of
514 nm, and the fluorescence intensity of DCF was measured at
an emission wavelength of 525 nm. Untreated cells served as
controls. The amount of intracellular ROS was expressed as the
fold-increase of DCF fluorescence compared with the control. The
experiments were repeated three times. The fluorescence intensity
of intracellular DCF was observed using a laser scanning confocal
microscope. The respective 3-dimensional horizontal plane images
were produced using a laser scanning confocal microscope, based
on the mean fluorescence intensity measured for the cells stained
with DCFHDA.
Small Interfering RNAs (siRNAs)
A double-stranded siRNA (DR5 siRNA) (sense, 59-GACC-
CUUGUGCUCGUUGUCTT-39, antisense 59-GACAACGAG-
CACAAGGGUCTT-39) was designed to target the DR5 gene
[53]. A nonspecific control siRNA (sense 59-UUCUCCGAAC-
GUGUCACGUTT-39; antisense 59-ACGUGACACG UUCG-
GAGAATT-39) was also designed. The siRNAs were produced by
GenePharma Co. Ltd., Shanghai, China. BxPC-3 and PANC-1
cells were grown to approximately 40–50% confluence in 6- or 96-
well plates and transfected with the siRNAs using Lipofectami-
ne
TM 2000 (Invitrogen) following the previously described method
in serum-free medium without antibiotic supplementation [54].
After incubation for 6 h, the culture medium was refreshed, and
the cells were cultured for an additional 72 h with Apo2L/TRAIL
and/or various concentrations of DHA. Silencing of protein
expression was confirmed by western blot analysis.
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The methodology has been described previously [30]. Briefly,
5610
5 cells were sonicated in RIPS buffer and homogenized, and
cellular debris was removed by centrifugation. The protein
contents of the cell and tumor tissue homogenates were de-
termined, and 30 mg protein samples were resolved on 12%
polyacrylamide SDS gels and electrophoretically transferred to
polyvinylidene difluoride membranes. The membranes were
blocked with 5% BSA, incubated first with primary antibodies,
and subsequently with an alkaline phosphatase-conjugated
secondary antibody. The membranes were then developed using
5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium
(Tiangen Biotech Co. Ltd., Beijing, China). The blots were
stained with an anti-b-actin AB to confirm that each lane
contained a similar amount of protein.
In vivo studies
All surgical and care procedures administered to the animals
were in accordance with institutional guidelines. Athymic, 6-week-
old nude mice were obtained from the Animal Research Center,
Dalian Medical University, China. Tumors were established by
subcutaneous injection of 5610
6 BxPC-3 cells into the flanks of the
mice. When the tumors reached sizes of approximately 120 mm
3,
the host mice were randomly assigned to four groups (6 in each
group): control (DMSO was dissolved in PBS and administered
once daily by i.p. injection), DHA (10 mg/kg, administered once
daily by i.p. injection), Apo2L/TRAIL (50 mg, administered once
daily by i.p. injection), and DHA+Apo2L/TRAIL, administered
following the same schedule as the individual drugs. Tumor size
was measured twice per week using calipers, and tumor volumes
were estimated according to the formula: p/66A
26B, where A
represents the short axis, and B represents the long axis. The mice
were closely monitored for 21 days prior to euthanization and
removal of the tumors. Each tumor was stored at 280uC for
further analysis.
Quantitation of PCNA proliferation index
The methodology has been described previously [9]. Briefly,
tumor sections were immunostained with anti-PCNA antibody.
Proliferating cells were quantified by counting the PCNA positive
(brown) cells and the total number of cells in 10 arbitrarily selected
fields at 6400 magnification by an independent observer. The
PCNA proliferation index was calculated as: the number of PCNA
positive cells/the total cell count 6100%.
In situ detection of apoptotic cells
The methodology has been described previously [9]. Tumor
sections were stained with TUNEL agent (Roche, Shanghai,
China). The apoptosis was evaluated by counting the positive cells
(brown-stained), as well as the total number of cells in 10
arbitrarily selected fields at6400 magnification by an independent
observer. The apoptotic index was calculated as: the number of
apoptotic cells/total number of nucleated cells 6100%.
Statistical analysis
Tumor growth patterns were compared using the analysis of
variance (ANOVA) test. Other results were expressed as the mean
values 6 standard deviations, and a Student’s t test was used to
evaluate statistical significance. A P value of less than 0.05 was
determined to be statistically significant.
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